Synapse - Robert Motzer

Results (1243)

Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial

Meeting Abstract

Bourlon, M. T.; Escudier, B.; Burotto, M.; Powles, T.; Apolo, A. B.; Shah, A. Y.; Porta, C.; Suárez, C.; Barrios, C. H.; Richardet, M.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Paclitaxel, ifosfamide, and cisplatin as initial salvage chemotherapy for germ cell tumors: Long-term follow-up and outcomes for favorable- and unfavorable-risk disease

Journal Article

Gleeson, J. P.; Knezevic, A.; Bromberg, M.; Patil, S.; Sheinfeld, J.; Carver, B. S.; Bains, M.; Jones, D. R.; Bajorin, D. F.; Bosl, G. J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Real-world treatment patterns and clinical outcomes of metastatic renal cell carcinoma patients post immune-oncology (IO) and vascular endothelial growth factor (VEGF) receptor targeted therapies

Meeting Abstract

Shah, N.; Sura, S.; Shinde, R.; Wentworth, C.; Conkling, P.; Bupathi, M.; Perini, R.; Vickery, D.; Motzer, R.
The Oncologist (2024)

Fulltext@MSK | Save

Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial

Meeting Abstract

Atkins, M. B.; Escudier, B.; McDermott, D. F.; Burotto, M.; Choueiri, T. K.; Hammers, H. J.; Plimack, E. R.; Porta, C.; George, S.; Powles, T.; more...
The Oncologist (2024)

Fulltext@MSK | Save

A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan (WELIREG(TM)) in patients with advanced or metastatic renal cell carcinoma, NCT06234605

Meeting Abstract

McKay, R. R.; Garmezy, B.; Barata, P.; Ornstein, M.; Shah, N. J.; Hammers, H.; Hutson, T. E.; Chisamore, M.; Karim, D.; Mattson, P.; more...
The Oncologist (2024)

Fulltext@MSK | Save

Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial

Meeting Abstract

Grünwald, V.; Motzer, R. J.; Keizman, D.; Bedke, J.; Schmidinger, M.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Avelumab plus axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial

Meeting Abstract

Motzer, R. J.; Penkov, K.; Uemura, H.; Campbell, M. T.; Kollmannsberger, C. K.; Lee, J. L.; Venugopal, B.; Van Den Eertwegh, A.; Negrier, S.; Gurney, H.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial

Meeting Abstract

Motzer, R. J.; Porta, C.; Eto, M.; Hutson, T. E.; Rha, S. Y.; Merchan, J. R.; Winquist, E.; Gurney, H.; Grünwald, V.; George, S.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Intratumoral T-cell infiltration and response to nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma from the CheckMate-214 trial

Meeting Abstract

Matar, S.; Jegede, O.; Denize, T.; Ghandour, F.; Laimon, Y. N.; El Ahmar, N.; Sheshdeh, A. B.; Savla, V.; Mohanna, R. A.; Catalano, P. J.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save

Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001

Meeting Abstract

Pal, S. K.; Medioni, J.; de Velasco, G.; Merchan, J. R.; Büchler, T.; Apolo, A. B.; Loriot, Y.; Wang, Z.; Jew, T.; Cao, A.; more...
Journal of Clinical Oncology (2024)

Fulltext@MSK | Save